Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica

Annals of Neurology

Volumn 71, Issue 3, 2012, Pages 314-322

  Tradtrantip, Lukmanee ^a   Zhang, Hua ^a   Saadoun, Samira ^b   Phuan, Puay Wah ^a   Lam, Chiwah ^c   Papadopoulos, Marios C ^b   Bennett, Jeffrey L ^c   Verkman, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EX VIVO STUDY; IN VIVO STUDY; MOUSE; MYELOOPTIC NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD; SURFACE PLASMON RESONANCE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; AQUAPORIN 4; BINDING SITES, ANTIBODY; BINDING, COMPETITIVE; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, KNOCKOUT; NEUROMYELITIS OPTICA; ORGAN CULTURE TECHNIQUES; PROTEIN BINDING; RECOMBINANT PROTEINS;

EID: 84862787794     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22657     Document Type: Article

References (42)

1. Jarius S, Paul F, Franciotta D, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008; 4: 202-214.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
3. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009; 256: 1891-1898.
4. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008; 131: 3072-3080.
5. Mader S, Lutterotti A, Di Pauli F, et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One 2010; 5: e10455.
6. Manley GT, Fujimura M, Ma T, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000; 6: 159-163.
7. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, et al. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997; 17: 171-180.
8. Jarius S, Wildemann B,. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383-392.
9. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
10. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66: 617-629.
11. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66: 630-643.
12. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009; 386: 623-627.
13. Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133: 349-361.
14. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69: 2221-2231.
15. Parratt JD, Prineas JW,. Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler 2010; 16: 1156-1172.
16. Cree B,. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep 2008; 8: 427-433.
17. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019-1032.
18. Baudino L, Nimmerjahn, F, Shinohara Y, et al. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. J Immunol 2008; 181: 4107-4112.
19. Duncan AR, Winter G,. The binding site for C1q on IgG. Nature 1988; 332: 738-740.
20. Hezareh M, Hessell AJ, Jensen RC, et al. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 2001; 75: 12161-12168.
21. Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166: 2571-2575.
22. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
23. Patel AR, Kanazawa KK, Frank CW,. Antibody binding to a tethered vesicle assembly using QCM-D. Anal Chem 2009; 81: 6021-6029.
24. Crane JM, Lam C, Rossi A, et al. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J Biol Chem 2011; 286: 16516-16524.
25. Saadoun S, Waters, P, MacDonald C, et al. T cell deficiency does not reduce lesions in mice produced by intracranial injection of NMO-IgG and complement. J Neuroimmunol 2011; 235: 27-32.
26. Zhang H, Bennett JL, Verkman AS,. Aquaporin-4-dependent neuromyelitis optics lesions produced by NMO-IgG in an in vitro spinal cord slice culture model. Ann Neurol (in press).
27. Hagemeyer CE, von Zur Muhlen C, von Elverfeldt D, et al. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost 2009; 101: 1012-1019.
28. Kontermann RE,. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009; 23: 93-109.
29. Igawa T, Tsunoda H, Kuramochi T, et al. Engineering the variable region of therapeutic IgG antibodies. MAbs 2011; 3: 243-252.
30. Nieri P, Donadio E, Rossi S, et al. Antibodies for therapeutic uses and the evolution of biotechniques. Curr Med Chem 2009; 16: 753-779.
31. Kaneko E, Niwa R,. Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs 2011; 25: 1-11.
32. Hinson SR, McKeon A, Fryer JP, et al. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 2009; 66: 1164-1167.
33. Marignier R, Nicolle A, Watrin C, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010; 133: 2578-2591.
34. Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008; 205: 2473-2481.
35. Papadopoulos MC, Manley GT, Krishna S, et al. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 2004; 18: 1291-1293.
36. Binder DK, Yao X, Zador Z, et al. Increased seizure duration and slowed potassium kinetics in mice lacking aquaporin-4 water channels. Glia 2006; 53: 631-636.
37. +-sensing fluorescent indicator. Nat Methods 2005; 2: 825-827.
38. Auguste KI, Jin S, Uchida K, et al. Greatly impaired migration of implanted aquaporin-4-deficient astroglial cells in mouse brain toward a site of injury. FASEB J 2007; 21: 108-116.
39. Saadoun S, Papadopoulos MC, Watanabe H, et al. Involvement of aquaporin-4 in astroglial cell migration and glial scar formation. J Cell Sci 2005; 118: 5691-5698.
40. Li L, Zhang H, Varrin-Doyer M, et al. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J 2011; 25: 1556-1566.
41. Verkman AS,. Mammalian aquaporins: diverse physiological roles and potential clinical significance. Expert Rev Mol Med 2008; 10: e13.
42. Ratelade J, Bennett JL, Verkman AS,. Evidence against cellular internalization in vivo of NMO-IgG, AQP4 and EAAT2 in neuromyelitis optica. J Biol Chem (in press).